Cochrane · systematic review · CD011599
Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema
Mehta, H, Hennings, C, Gillies, MC, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
23
current version
GRADE rated
13
No studies
10
Included studies
NR
No studies 10 · 43.5%Ungraded 0 · 0%Very low 4 · 17.4%Low 7 · 30.4%Moderate 2 · 8.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid versus intravitreal anti‐VEGF for diabetic macular oedema
Population: adults with centre‐involving diabetic macular oedema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mean change in visual acuity at 1 year (number of letters read on logMAR chart) Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid vs intravitreal anti‐VEGF | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision |
Mean change in central macular thickness at 1 year Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid vs intravitreal anti‐VEGF | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision |
Significant intraocular inflammation at Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid vs intravitreal anti‐VEGF | Peto OR 0.53 [0.05, 5.08] | NR | Very low Downgraded: risk of bias, imprecision |
Development of cataract at Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid vs intravitreal anti‐VEGF | Peto OR 7.49 [2.87, 19.6] | NR | Moderate Downgraded: risk of bias, imprecision |
Raised intraocular pressure at Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid vs intravitreal anti‐VEGF | Peto OR 8.13 [4.67, 14.16] | NR | Moderate Downgraded: risk of bias, imprecision |
Systemic adverse events at Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid vs intravitreal anti‐VEGF | Peto OR 1.32 [0.61, 2.86] | NR | Low Downgraded: risk of bias, imprecision |
Quality of life at Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid vs intravitreal anti‐VEGF | no estimate extracted | NR | No studies |
Summary of findings: intravitreal bevacizumab plus intravitreal steroid versus macular laser for diabetic macular oedema
Population: adults with centre‐involving diabetic macular oedema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mean change in visual acuity at 1 year (number of letters read on logMAR chart) Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision |
Gain or loss of 10 or more letters visual acuity at 1 year Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser | no estimate extracted | NR | No studies |
Mean change in central macular thickness at 1 year Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision |
Significant intraocular inflammation at Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser | no estimate extracted | NR | No studies |
Development of cataract at Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser | Peto OR 4.58 [0.99, 21.1] | NR | Very low Downgraded: risk of bias, imprecision |
Raised Intraocular Pressure at Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser | Peto OR 9.49 [2.86, 31.51] | NR | Very low Downgraded: risk of bias, imprecision |
Systemic adverse events at Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser | no estimate extracted | NR | No studies |
Quality of life at Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser | no estimate extracted | NR | No studies |
Summary of findings: intravitreal bevacizumab plus intravitreal steroid versus intravitreal steroid for diabetic macular oedema
Population: adults with centre‐involving diabetic macular oedema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mean change in visual acuity at 1 year (number of letters read on logMAR chart) Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision |
Gain or loss of 10 or more letters visual acuity at 1 year Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid | no estimate extracted | NR | No studies |
Mean change in central macular thickness at 1 year Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid | no estimate extracted | NR | Low Downgraded: risk of bias, imprecision |
Significant intraocular inflammation at Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid | no estimate extracted | NR | No studies |
Development of cataract at Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid | no estimate extracted | NR | No studies |
Raised intraocular pressure at 1 year at Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid | Peto OR 0.75 [0.16, 3.55] | NR | Very low Downgraded: risk of bias, imprecision |
Systemic adverse events at Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid | no estimate extracted | NR | No studies |
Quality of life at Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid | no estimate extracted | NR | No studies |